Marketing Alliance of Daewoong Pharm – Astra Zeneca Korea for the Sales of ‘Symbicort’

- Symbicort, the fast and effective drug for sustained bronchodilator effect

-Anticipated synergy effect of the excellent product with an effective sales force



Daewoong Pharm. Co., Ltd. (CEO Jong Wook Lee) and Astra Zeneca Korea (CEO Sang Jin Park) have signed an agreement on the co-promotion of ‘Symbicort (active ingredients: budesonide, formoterol)’ or the asthma treatment in inhaling type and became the strategic alliance for domestic sales and marketing. It was the second time of the alliance between two companies after the one on ‘Nexium’ or the drug for gastroesophageal reflux disease.
The CEO Lee of Daewoong Pharm. said, “the proven superior efficacy of the product, Symbicort will meet the sales force of Daewoong which is the No. 1 in domestic sales of the prescription drugs to create the synergy effects.” He also emphasized, “Through this partnership, which adds Symbicort to the existing treatment drugs, Erdos (expectorant) and Alrerak (allergy treatment), the competitiveness has been enhanced in the respiratory market.”

The CEO Park of Astra Zeneca Korea announced, “The synergy effect between the scientific marketing of Astra Zeneca and the firm sales force of Daewoong Pharm. has high expectations. Based on the successful experience with ‘Nexium’ this alliance will provide the benefits of Symbicort, the inhaling type of asthma treatment with safety and efficacy to many patients and clinicians.”

Symbicort is the treatment for asthma and chronic obstructive pulmonary disease (COPD) released domestically in 2001. It is a new concept of the asthma treatment which allows the ordinary asthma control (treatment for the airway inflammation) and emergency relief of symptoms (bronchodilator) with a single inhaler. In particular, the smart method of Symbicort decreases the frequency of worsening asthma and it can also be used as a substitute for the emergency bronchodilator improving the inconvenience with previous treatments which made the patients carry multiple inhalers. [1] In clinical researches of more than 16,000 asthma patients, Symbicort was proven to have the excellent asthma control effects with rapidness and long-lasting bronchodilator effect.